Vitrakvi set to become EU’s first tissue-agnostic cancer drug
EMA's CHMP delivered its first positive recommendation for a tissue-agnostic cancer therapy to Vitrakvi in its monthly basket of positive opinions, which also included one for GW’s Epidyolex.
CHMP backed approval of an MAA from Bayer AG (Xetra:BAYN) for Vitrakvi larotrectinib to treat